Cancer immunotherpay

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 3/November/2018, 11. 38 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 3/November/2018, 11. 38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e…

read more

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Mifepristone, an abortion-promoting drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 11.24 am
The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Mifepristone, an abortion-promoting drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 11.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as APAF, Foxo1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 29/July/2018, 11.24 pm
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as APAF, Foxo1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 29/July/2018, 11.24 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing  Lovastatin, Lofepiramine, AUY922,  Temozolomide, Salinomycin, 5-Fluro-2’deoxycytidine (LLATSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/June/2018, 10.24 pm
Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing  Lovastatin, Lofepiramine, AUY922,  Temozolomide, Salinomycin, 5-Fluro-2’deoxycytidine (LLATSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/June/2018, 10.24 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more

Molecular therapy for Cancer: A therapeutic mix encompassing N-Acetyl Cysteine (NAC),  SAHA, Amitriptyline, 17-DMAG and Rosuvastatin (NSADR) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 16/February/2017, 11.04 pm
Molecular therapy for Cancer: A therapeutic mix encompassing N-Acetyl Cysteine (NAC),  SAHA, Amitriptyline, 17-DMAG and Rosuvastatin (NSADR) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 16/February/2017, 11.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA and Laboratory of Genetics, Salk Institute for Biological Studies, La…

read more

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Panaxynol, Procainamide, Pitavastatin,  Protriptyline, Salinomycin  And Temozolomide (PPPPSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/January/2018, 9.14 am
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Panaxynol, Procainamide, Pitavastatin,  Protriptyline, Salinomycin  And Temozolomide (PPPPSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/January/2018, 9.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more
Start Typing